Finnegan Celebrates Two Wins at the 2020 LMG Life Sciences Awards and Top Honors in the Rankings

FOR IMMEDIATE RELEASE
October 5, 2020

WASHINGTON, DC—At the 2020 LMG Life Sciences Awards virtual ceremony, Finnegan received the awards for “Patent Strategy Firm of the Year” and “Patent Impact Case of the Year.”

The “Patent Impact Case of the Year” award reflects the firm’s appellate victory in Kaken Pharmaceutical Co., Ltd.; Bausch Health Care v. Andrei Iancu. At the U.S. Court of Appeals for the Federal Circuit, on behalf of clients Kaken Pharmaceuticals and Bausch Health, Finnegan obtained a decision reviving a key patent covering the Jublia^® pharmaceutical product directed to methods of using efinaconazole to treat onychomycosis. In the case on appeal from an inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB), Finnegan argued that the final written decision finding the patent obvious and therefore unpatentable was based on an erroneous claim construction ruling. The Federal Circuit agreed and issued a precedential opinion overturning the PTAB’s claim construction of a key term in the patent, reversing the PTAB’s finding of obviousness that led to the finding of unpatentability, and remanding the case back to the Board. The patent at issue, which is being asserted in multiple concurrent district court litigations, provides patent protection for Jublia^® until 2026. Jublia^® has achieved more than $1B in sales since launch.

LMG’s Patent Strategy Firm of the Year award recognizes Finnegan’s strength in working with innovators dedicated to creating life-saving and life-improving products, proving first-hand how deliberate and holistic IP asset protection makes the difference, particularly when it comes to enforcing rights to keep competitors at bay or defending against infringement allegations.

In addition to receiving two awards, the firm once again received top honors in the LMG Life Sciences rankings. Finnegan ranked as “highly recommended” in the intellectual property categories of Patent Prosecution, Patent Strategy & Management, General Patent Litigation, and Hatch-Waxman Patent Litigation (Branded). Finnegan’s Life Sciences practice includes more than 250 attorneys and professionals dedicated to serving our clients’ intellectual property needs in the biologics, biotechnology, branded Hatch-Waxman (ANDA), digital health, medical device and diagnostics, and pharmaceutical spaces. The following attorneys were ranked as 2020 LMG Life Sciences Stars:

Michele C. Bosch - General Patent Litigation, Patent Strategy & Management

Scott Burwell - General Patent Litigation, Hatch-Waxman Patent Litigation

Bryan C. Diner - Hatch-Waxman Patent Litigation, Patent Strategy & Management

Thomas L. Irving - Patent Prosecution, Patent Strategy & Management, General Patent Litigation

Michael Jakes - General Patent Litigation, Patent Strategy and Management

Howard W. Levine - General Patent Litigation, Hatch-Waxman Patent Litigation, Patent Strategy & Management

Charles E. Lipsey - General Patent Litigation, Hatch-Waxman Patent Litigation

John D. Livingstone - Hatch-Waxman Patent Litigation

Jill K. MacAlpine, Ph.D. - General Patent Litigation, Patent Strategy & Management, Hatch-Waxman Patent Litigation, Patent Prosecution

Leslie A. McDonell - Patent Prosecution, Patent Strategy & Management, General Patent Litigation

James B. Monroe - General Patent Litigation

William B. Raich, Ph.D. - General Patent Litigation

Barbara R. Rudolph Ph.D. - General Patent Litigation, Hatch-Waxman Patent Litigation

Contacts
Anand K. Sharma, Managing Partner 
anand.sharma@finnegan.com 

Mark D. Sweet, Chair 
mark.sweet@finnegan.com 

About Finnegan
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices all aspects of patent, trademark, and copyright, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to advertising, trade secret law, European patents and trade marks, international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. Follow us on LinkedIn and Twitter.